Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in this process. Understanding the potential mechanism of action of BTK inhibition in SARS-CoV-2 is clearly of importance to determine how acalabrutinib, ibrutinib and possibly other BTK inhibitors may provide protection against lung injury.
【저자키워드】 COVID-19, SARS-CoV-2, Cancer, Bruton’s tyrosine kinase, Ibrutinib, Acalabrutinib, IL-1β, 【초록키워드】 Cytokines, Lung disease, drug, Lung injury, severe acute respiratory syndrome Coronavirus, inhibitors, innate immune system, Severe acute respiratory syndrome, Patient, understanding, pro-inflammatory cytokines, Ibrutinib, Acalabrutinib, pulmonary injury, circulation, respiratory, COVID-19 patients, Coronavirus-2, BTK, COVID-19 patient, tyrosine, acute respiratory syndrome, acute respiratory syndrome coronavirus, potential mechanism, acute respiratory syndrome coronavirus-2, BTK inhibitor, pro-inflammatory cytokine, PROTECT, determine, infected with SARS-CoV-2, 【제목키워드】 tyrosine kinase inhibitor, SAR-CoV-2, observation,